← Back to Screener
Context Therapeutics Inc. Common Stock (CNTX)
Price$2.26
Favorite Metrics
Price vs S&P 500 (26W)53.39%
Price vs S&P 500 (4W)-33.30%
Market Capitalization$207.65M
All Metrics
Book Value / Share (Quarterly)$0.66
P/TBV (Annual)0.40x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.29
Price vs S&P 500 (YTD)49.81%
EPS (TTM)$-0.38
10-Day Avg Trading Volume0.83M
EPS Excl Extra (TTM)$-0.38
EPS (Annual)$-0.38
ROI (Annual)-59.73%
Cash / Share (Quarterly)$0.72
ROA (Last FY)-52.74%
EBITD / Share (TTM)$-0.41
ROE (5Y Avg)-70.80%
Cash Flow / Share (Annual)$-0.29
P/B Ratio3.43x
P/B Ratio (Quarterly)2.23x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-208.20x
ROA (TTM)-44.07%
EPS Incl Extra (Annual)$-0.38
Current Ratio (Annual)8.52x
Quick Ratio (Quarterly)8.25x
3-Month Avg Trading Volume1.33M
52-Week Price Return168.06%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.15
52-Week High$3.62
EPS Excl Extra (Annual)$-0.38
26-Week Price Return60.28%
Quick Ratio (Annual)8.25x
13-Week Price Return48.68%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.52x
Enterprise Value$141.652
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.72
3-Month Return Std Dev94.18%
Net Income / Employee (TTM)$-3
ROE (Last FY)-59.73%
EPS Basic Excl Extra (Annual)$-0.38
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.38
ROI (TTM)-47.04%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.18
Price vs S&P 500 (52W)133.43%
Year-to-Date Return53.74%
5-Day Price Return-9.96%
EPS Normalized (Annual)$-0.38
ROA (5Y Avg)-57.73%
Month-to-Date Return-13.74%
Cash Flow / Share (TTM)$-1.30
EBITD / Share (Annual)$-0.41
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-70.80%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.38
P/TBV (Quarterly)0.75x
P/B Ratio (Annual)2.23x
Book Value / Share (Annual)$0.66
Price vs S&P 500 (13W)46.30%
Beta1.61x
Revenue / Share (TTM)$0.00
ROE (TTM)-47.04%
52-Week Low$0.49
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.19
4.19
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CNTXContext Therapeutics Inc. Common Stock | — | — | — | — | $2.26 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.71 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Context Therapeutics is a clinical-stage biopharmaceutical company developing targeted immunotherapies for solid tumors, with an initial focus on hormone-dependent cancers in women, including breast, ovarian, and endometrial cancer. Its lead program, CTIM-76, is a bispecific antibody that redirects T-cells to attack cancer cells expressing CLDN6, combining immune activation with tumor-specific targeting. The company aims to deliver efficacy while minimizing off-target effects through this precision approach.